Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Cellular therapies like CAR T-cell therapy and hematopoietic cell transplantation (HCT), long used in blood cancers, are showing real promise for autoimmune diseases like multiple sclerosis and rheumatologic conditions. ASTCT and CBCI are hosting a first-of-its-kind multidisciplinary meeting in October to help clinicians navigate this fast-evolving space. The goal: better patient selection, safer toxicity management, and stronger cross-specialty collaboration.
Cellular therapies are crossing into autoimmune disease territory — and clinicians need to be ready.
Treatments like CAR T-cell therapy and autologous hematopoietic cell transplantation (HCT), which revolutionized care for blood cancers, are now showing strong early results in autoimmune conditions including multiple sclerosis, scleroderma, and rheumatologic diseases. The key concept driving this shift: "immune reset" — using deep immune depletion to potentially eliminate autoreactive immune cells in tissues and lymph nodes, offering more durable remission than traditional disease-modifying agents.
To help clinicians get up to speed, the American Society for Transplantation and Cellular Therapy (ASTCT) and the Colorado Blood Cancer Institute (CBCI) are hosting the inaugural Meeting on Transplantation and Cellular Therapy for Immunological Disorders on October 1–2 in Aurora, Colorado. The event will unite transplant specialists, cellular therapy experts, neurologists, and rheumatologists to share clinical experience and tackle key operational challenges.
Key Takeaways:
Why it matters: As cellular immunotherapies move into the autoimmune space, the field is evolving faster than most clinicians can track. This meeting aims to build the community and cross-specialty infrastructure needed to safely and effectively bring these potentially transformative therapies to a much broader patient population.
